Cardiovascular diseases (CVDs) are a leading cause of mortality and have an earlier onset in India. Bioresorbable stents (scaffolds) offer an alternative treatment option in addition to metallic stent implants. Meril Life Sciences is committed to introduce BRS therapy via a sequential roll out in